首页> 美国卫生研究院文献>Oncotarget >New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer
【2h】

New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer

机译:Ki-67标记指数对三阴性乳腺癌患者预后价值的新见解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The clinicopathological importance of the Ki-67 labeling index (LI) in breast cancer has been studied intensely; however, its prognostic significance in triple-negative breast cancer (TNBC) is unclear. We aimed to determine the optimal Ki-67 cut-off point to demonstrate its prognostic relevance for breast-cancer-specific survival (BCSS) in TNBC patients. A total of 571 female TNBC patients underwent diagnosis and surgery at our institution from January 2002 to June 2011. Clinicopathological information for all patients was available and categorized by Ki-67 LI and age at diagnosis. The cut-off values for Ki-67 LI and age were selected using the medians. A varying-coefficient Cox model was used to describe the effect of Ki-67 LI on BCSS outcomes changing with age after adjustment for disease characteristics. For survival analysis, the Kaplan–Meier method and the log-rank test were used. Cox proportional hazards models were applied to determine the association of Ki-67 LI and age with BCSS outcomes after adjustment for disease characteristics. Median age was 50 years, and median Ki-67 LI was 35% (range, 0 – 97.5%). There was no prognostic significance of stratification by Ki-67 LI in all patients. When analyzing age at diagnosis as a continuous variable, the log-transformed HRKi67 > 35% vs. ≤ 35% for BCSS increased in an S-shaped curve with increasing age up to about 50 years-old and remained higher-risk for high Ki-67 LI. After adjusting for clinicopathological risk factors, low Ki-67 LI was a poor prognostic factor for BCSS (HR: 0.36, 95% CI: 0.14–0.96, P = 0.042) in patients of ≤ 50 years, but not in patients diagnosed at > 50 years (hazard ratio [HR]: 1.57, 95% CI: 0.76–3.22, P = 0.241). In conclusion, lower Ki-67 LI has poor prognosis relevance in TNBC patients diagnosed at ≤ 50 years-old. Further validation of the clinical significance of Ki-67 LI in TNBC is required.
机译:Ki-67标记指数(LI)在乳腺癌中的临床病理学重要性已得到深入研究。然而,其在三阴性乳腺癌(TNBC)中的预后意义尚不清楚。我们旨在确定最佳的Ki-67临界值,以证明其与TNBC患者乳腺癌特异性生存(BCSS)的预后相关性。从2002年1月至2011年6月,本机构共571例女性TNBC患者接受了诊断和手术。所有患者的临床病理信息均可用Ki-67 LI和诊断时的年龄分类。使用中位数选择Ki-67 LI和年龄的临界值。调整疾病特征后,使用变系数Cox模型描述Ki-67 LI对BCSS结果随年龄变化的影响。为了进行生存分析,使用了Kaplan-Meier方法和对数秩检验。校正疾病特征后,应用Cox比例风险模型确定Ki-67 LI和年龄与BCSS结果的关联。中位数年龄为50岁,Ki-67 LI中位数为35%(范围为0 – 97.5%)。在所有患者中,使用Ki-67 LI分层均无预后意义。当将诊断时的年龄作为连续变量进行分析时,BCSS的对数转换HRKi67> 35%vs≤35%呈S形曲线增加,随着年龄的增长,年龄增加到约50岁,高Ki风险仍然较高-67李。调整临床病理危险因素后,对于≤50岁的患者,低Ki-67 LI是BCSS的不良预后因素(HR:0.36,95%CI:0.14-0.96,P = 0.042),但对于诊断为> 50年(危险比[HR]:1.57,95%CI:0.76-3.22,P = 0.241)。总之,在诊断为≤50岁的TNBC患者中,较低的Ki-67 LI预后相关性较差。需要进一步验证Ki-67 LI在TNBC中的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号